Gewinn- und Verlustrechnung von Hyperfine, Inc.

[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered

GUILFORD, Conn.--(BUSINESS WIRE)--FDA-cleared Optive AI software enhances Swoop system image quality, clinical utility, ease of use, and isotropic imaging capability.

Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript

Hyperfine NASDAQ: HYPR reported second-quarter revenue of $3.9 million, up approximately 45% from a year earlier, as the portable MRI company cited growth across hospital, neurology office and international markets.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2026 financial results and provided a business update. “Q2 was another strong quarter for Hyperfine, marked by solid growth in placements and revenue, continued gross margin expansion, disciplined operating expense.

GUILFORD, Conn.--(BUSINESS WIRE)--Multiple peer-reviewed publications in Journal of Neurosurgery and Stroke strengthen evidence for portable MRI in stroke and neurosurgical settings.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine will report Q2 2026 financial results Thur., Aug. 6, 2026. Management will host a corresponding conference call at 1:30 PM PT/4:30 PM ET.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine initiates the launch of the next-gen Swoop® system in Europe, beginning global expansion of its most advanced portable MRI technology. ‌.

GUILFORD, Conn.--(BUSINESS WIRE)--Leading neurosurgeons will help guide the role of the Swoop® system in neurosurgical care, including workflow, product capabilities, and evidence.

[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powere